COMMUNIQUÉS West-GlobeNewswire

Sierra Donor Services New Mexico Honors Local Donor Heroes During National Multicultural Donor Awareness Month
14/08/2026
ALBUQUERQUE, N.M., Aug. 14, 2026 (GLOBE NEWSWIRE) -- During the month of August, Sierra Donor Services New Mexico recognizes National Multicultural Donor Awareness Month by honoring the diverse donor heroes in the state [...]
Jasper Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
14/08/2026
Acquisition of Kira Pharmaceuticals closed in July creating a combined company with a robust portfolio of clinical stage assets focused on immunologically-driven disorders Completed a concurrent PIPE financing raising $ [...]
Silexion Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
14/08/2026
Successfully transitioned SIL204 from regulatory preparation into an active Phase 2/3 clinical program in locally advanced pancreatic cancer, with trial initiation at Tel Aviv Sourasky Medical Center in July 2026 [...]
Vivos Therapeutics Schedules Release of Second Quarter 2026 Financial Results and Conference Call
14/08/2026
Call scheduled for today, Friday, August 14, 2026, at 5:00 pm ET LITTLETON, Colo., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and [...]
NOMAD POWER SOLUTIONS FILES 2026 SECOND QUARTER FORM 10-Q, PROVIDES BUSINESS UPDATE
14/08/2026
Among Recent Developments: -Corporate Name Change- -Acquisition of Leading AI Energy Infrastructure Equipment/Services Provider- -Addition to Board of Renowned Energy Sector Executive- -Key Leadership Appointments at [...]
Vistagen Reports Fiscal Year 2027 First Quarter Financial Results and Corporate Update
14/08/2026
Exploratory analyses of patients with very severe social anxiety disorder demonstrated nominally statistically significant improvement in recently reported clinical studies FDA engagement planned during the current [...]
BiomX Subsidiary Zorronet Receives Approximately $300,000 Purchase Order to Build Unified Operational Environment at Defense Technology Test and Evaluation Site
14/08/2026
Strategic project expands Zorronet’s presence in defense technology test and evaluation environments and includes site infrastructure, systems integration, a dedicated command-and-control center and coordination with [...]
Sienna Announces August Dividend
14/08/2026
MARKHAM, Ontario, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. (“ Sienna ” or the “ Company ”) (TSX: SIA) today announced a dividend of $0.078 per common share of the Company (each, a “ Common Share ”) [...]
Quoin Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2026 Financial Results
14/08/2026
– Receives FDA Conditional Approval of QYLEKI™ as the Proposed Brand Name for QRX003 for Netherton Syndrome – Reports Positive Clinical Update from Ongoing Pediatric Compassionate Use Program in Netherton Syndrome – [...]
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
14/08/2026
BOSTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, [...]
Moleculin Biotech Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of Pivotal MIRACLE Trial
14/08/2026
Positive interim MIRACLE data showed complete remission rates three times higher than control in relapsed/refractory AML MIRACLE trial advancing toward planned 90-patient enrollment milestone in September 2026 with the [...]
Clene Reports Second Quarter 2026 Financial Results and Recent Operating Highlights
14/08/2026
Clene expects to submit a New Drug Application for CNM-Au8® in ALS under the accelerated approval pathway in early fourth quarter of 2026 Clene announces survival and functional benefit in CNM-Au8-treated patients whose [...]
TOMI Environmental Solutions, Inc. Reports Second Quarter 2026 Financial Results
14/08/2026
Company Delivers 118% Q2 Revenue Growth, Reaffirms Full-Year 2026 Guidance of $12 Million (113% YoY Growth) FREDERICK, Md., Aug. 14, 2026 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc. (NASDAQ: TOMZ), a global [...]
SCIENTURE Reports Q2 2026 Results with Approximately 510% Sequential Revenue Growth from Q1 2026 and Significant Improvement in Operating Performance
14/08/2026
Q2 2026 Gross Margin Was Approximately 97.7%, Reflecting the Company's Growing Commercial Revenue Base Q2 2026 Operating Loss Improved Approximately 48% Year-over-Year to Approximately $2.7 Million Q2 2026 Net Loss [...]
Galectin Therapeutics Reports June 30, 2026 Financial Results and Provides Business Update
14/08/2026
NORCROSS, Ga., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business [...]
Evaxion to announce business update and second quarter 2026 financial results on August 20, 2026
14/08/2026
COPENHAGEN, Denmark, August 14, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, will provide a business update and [...]
Allarity Therapeutics Reports Second Quarter 2026 Results and Completion of the Phase 3-Ready Stenoparib Manufacturing Campaign
14/08/2026
- Completed quarter with $26.9 million in cash and restricted cash - Key U.S. patent was awarded, protecting exclusivity of stenoparib when used with the stenoparib-specific DRP ® companion diagnostic into 2042 - AACR [...]
PMV Pharmaceuticals Reports Second Quarter 2026 Financial Results and Corporate Highlights
14/08/2026
Enrollment of platinum-resistant/refractory ovarian cancer patients for the primary analysis in the Phase 2 monotherapy portion of the PYNNACLE clinical trial completed Rezatapopt NDA submission for platinum-resistant/ [...]
GT Biopharma Reports Second Quarter 2026 Financial Results
14/08/2026
Phase 1 trial evaluating GTB-3650 TriKE ® remains ongoing, with an update anticipated in 2H 2026 Phase 1 basket trial evaluating GTB-5550 TriKE ® in multiple solid tumor types known to express B7-H3 initiated May 2026 [...]

Pages